Clinical Trial Update: Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating intravenous secukinumab demonstrated efficacy, safety, and tolerability in active psoriatic arthritis, with results posted after comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2024-04-26